CompletedNCT00083954
Quetiapine versus placebo for depression in bipolarity
About this title
Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression
Read the official source — NCT00083954Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 35 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 530
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00083954
- Official title
Show the full official title
A Confirmatory Multicenter, Double-blind, Randomized, Placebo Controlled Study of the Use of Quetiapine Fumarate (SEROQUEL) in the Treatment of Patients With Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham · Scottsdale · Cerritos
33 more locations
- Garden Grove
- San Diego
- Torrance
- Jacksonville
- Maitland
- Orlando
- Winter Park
- Boise
- Oak Brook
- Overbrook Terrace
- Shreveport
- Baltimore
- Clementon
- Moorestown
- Albuquerque
- Brooklyn
- New York
- Staten Island
- Raleigh
- Cincinnati
- Dayton
- Oklahoma City
- Portland
- Philadelphia
- Pittsburgh
- Charleston
- Memphis
- Austin
- Houston
- Salt Lake City
- Bellevue
- Kirkland
- Seattle
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine Fumarate.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
